News and Trends 25 May 2022 Duke Street Bio enters stage with next-generation cancer therapies The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline […] May 25, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2022 Vaccines mobilized to control monkeypox outbreak An unusual outbreak of monkeypox is causing concern worldwide in the shadow of the destructive Covid-19 pandemic. Both old and emerging vaccine technology could aid the fight against the outbreak. In the wake of the world-changing Covid-19 pandemic, the World Health Organization (WHO) is voicing alarm over another unusual outbreak, this time of the viral […] May 24, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2022 Zealand Pharma’s drug for rare metabolic disease smashes phase III After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial. In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the […] May 20, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 Evotec, Sernova in partnership to develop beta cell diabetes therapy Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in Sernova. Germany-based Evotec and Canada’s Sernova have agreed on a partnership to develop and commercialize an implantable diabetes therapy based on beta cell […] May 19, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 F2G enlists Shionogi to bring antifungal treatment to Europe and Asia The UK company F2G Ltd. has announced a strategic collaboration with Japanese pharmaceutical company Shionogi & Co. Ltd. to develop and commercialize olorofim, an antifungal treatment for invasive fungal infections, in Europe and Asia. The deal centers on olorofim, F2G’s oral antifungal therapy for the treatment of invasive aspergillosis, an infection that can be deadly […] May 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2022 US Giant Apollo Bags Billion-Euro Partnership with Sofinnova As biotech investment slows following a record-breaking year, the Paris-based Sofinnova Partners has landed a €1B collaboration deal with the US investment heavyweight Apollo to nurture life sciences companies. Cementing the trend for transatlantic deals between biotech investors, the US asset manager Apollo has entered into a billion-Euro partnership with the European venture capitalist (VC) […] May 17, 2022 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2022 Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags The stock price of the French Covid-19 vaccine maker Valneva has been knocked down by 20% as the company faces losing a supply contract with the European Commission. Despite receiving a glowing marketing authorization from the UK’s drug regulator in April this year, Valneva is struggling to gain traction with its Covid-19 vaccine in the […] May 16, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2022 Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round to move its lead candidate to clinical trials. The approval of the first immune checkpoint inhibitor treatments in 2014 proved a gamechanger for cancer immunotherapy as they prevented tumors […] May 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2022 The Top European Biotech Investments in April 2022 Private biotech investments in Europe were on a steady decline in April 2022 as biotech public markets continued to disappoint. The top funding rounds were dominated by UK and Swiss firms targeting genetic diseases and cancer. April 2022 provided no relief for the European biotech industry as public stock markets remain anemic. Though flush with […] May 12, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2022 eureKARE Launches €150M Merger to Form Cell and Gene Therapy CDMO The French startup creator eureKARE has set up a special purposes acquisition company (SPAC) with the ambition to merge multiple European contract development and manufacturing organizations into a heavyweight serving developers of gene therapies, protein drugs, and microbiome therapeutics. Over the last few years, record levels of funding have flowed into the biotech industry, particularly […] May 10, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 May 2022 Melt&Marble Gains €5M to Brew Fat Alternatives Using Engineered Yeast Tapping into the increasingly sophisticated market for meat alternatives, the Swedish synthetic biology startup Melt&Marble has raised €5M in seed financing to fund the development of a fermented fat ingredient that mimics the complex properties of beef fat. Companies are racing to enhance the flavor, melt, and mouthfeel of meat alternative products such as plant-based […] May 6, 2022 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2022 Amphista Lands Megadeals to Smash Cancer using Protein Degradation As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […] May 5, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email